20 April 2018 - Deborah Wilkes
Moberg Pharma is seeking a new vice president of research and development to replace Kjell Rensfeldt.
The Swedish company said Rensfeldt would retire from the post on 1 October 2018 but remain with the company as a senior adviser on a part-time basis. He joined Moberg in 2007.
Chief executive officer Peter Wolpert said Rensfeldt had been instrumental in the development of the fungal nail treatments Kerasal Nail and MOB-015.
Kerasal Nail was Moberg's largest product in 2017 with sales up by 2% in local currencies to SEK154 million (USD188 million).
Worldwide sales at Moberg reached SEK439 million in 2017, representing a rise of 31% in local currencies compared to the same period a year earlier. The rise as reported was also 31%.
Earnings Before Interest and Taxes (EBIT) for 2017 amounted to SEK51.1 million, compared with SEK66.2 million in the same period a year earlier.
Upgrade to an Annual Subscription to the OTCToolbox website, giving you UNLIMITED ACCESS to all of our publications
* OTCToolbox Innovations magazine NEW IDEAS BETTER WAYS
* OTCToolbox Deals Database
* Premium News Stories
* News Extras
* OTC Deal Trends Briefing
* OTC Company Strategies Report
Helping you and your company make well-informed decisions
CLICK HERE TO FIND OUT MORE